ALSO NOTED: Catalyst prices IPO; Hollis-Eden raises money; and much more...

> Catalyst Pharmaceutical Partners has priced its IPO of 3.4 million shares at $6 per share. Report

> Hollis-Eden Pharma is raising $26 million from the sale of shares. Report

> Medarex and PacMab struck a deal to market antibody-based drugs for blood cancer. Details of the deal were not released. Report

> Boehringer Ingelheim is touting three new anti-cancer therapies during its R&D press conference today. Release

> A group of Mayo Clinic-affiliated researchers studying arthritis drugs has publicly apologized for failing to fully disclose financial ties to the pharmaceutical industry. The researchers, who looked at cancer risks among patients taking Remicade, Enbrel and Humira for rheumatoid arthritis, published the results of their study last year in the Journal of the American Medical Association. Report

And Finally… The World Health Organization tapped the noted bird flu expert Dr. Margaret Chan, a Chinese national, to be its next director-general. Article

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.